Fielder Capital Group LLC Buys New Shares in Zoetis Inc. (NYSE:ZTS)

Fielder Capital Group LLC bought a new position in shares of Zoetis Inc. (NYSE:ZTS) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 2,945 shares of the company’s stock, valued at approximately $480,000.

Several other large investors have also recently bought and sold shares of ZTS. Atlantic Edge Private Wealth Management LLC boosted its holdings in shares of Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after buying an additional 140 shares during the last quarter. Darwin Wealth Management LLC acquired a new position in Zoetis during the third quarter worth $31,000. First Personal Financial Services bought a new stake in Zoetis during the third quarter worth $33,000. Capital Performance Advisors LLP acquired a new stake in Zoetis in the third quarter valued at $33,000. Finally, Dunhill Financial LLC grew its position in shares of Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after acquiring an additional 75 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ZTS has been the subject of several recent analyst reports. Barclays raised their target price on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Leerink Partners began coverage on Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price for the company. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Stifel Nicolaus cut their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Finally, UBS Group assumed coverage on shares of Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $215.90.

Zoetis Price Performance

Shares of Zoetis stock opened at $164.95 on Friday. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The stock has a market capitalization of $73.86 billion, a price-to-earnings ratio of 30.16, a price-to-earnings-growth ratio of 2.78 and a beta of 0.90. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53. The company has a 50-day simple moving average of $166.25 and a two-hundred day simple moving average of $177.49.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. The company had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.21%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s payout ratio is currently 36.56%.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is owned by insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.